الفهرس 
Cancer chemoprevention by metformin hydrochloride compared to placebo in oral potentially malignant lesions: a randomized clinical trial
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 220 |  |  |
| | | from | 220 | | |
Abstract
objective The aim of this study was to compare the effect of systemic Metformin hydrochloride on oral potentially malignant disorders (OPMDs) to Placebo regarding its efficacy in regression or suppression of the progress into frank cancer.study design Randomized controlled clinical trial.setting Oral Medicine Department Clinic, Faculty of Dentistry, Cairo University, Egypt and Faculty of Badr University in Cairo, Egypt.subjects and methodsThe trial was conducted with two arms parallel groups, with each group consisting of 20 non diabetic patients suffering from oral potentially malignant lesions, namely leukoplakia and oral lichen planus. Each group received either Metformin hydrochloride at a single daily dose of 500 mg or a placebo.Recommended standard health and dental care was given to both groups and risk factors were eleminated. Clinical and dental data, biopsies, immunohistochemical staining with cyclin{u00AD}A2 and miRNA{u00AD}31 were performed at baseline and at 3 months point results When compared to placebo, Metformin proved to control the progression of oral potentially malignant lesions, particularly with its ability to decrease significantly the lesions size, decrease Cyclin{u00AD}A2 expression from 163.0 to 147.5 and miRNA{u00AD}31 levels in both tissues and saliva were measued and were found to be in placebo group (in tissue) 7.5 and in Metformin group (in tissues) 4.0. While, Placebo group (in saliva) was found to be 7.0 and Metformin group (in saliva) was 5.0